HOME › Research Insight › Life Technologies, QIAGEN N.V., Affymetrix, and Illumina, among others Dominate the Gene Expression Analysis Market
Life Technologies, QIAGEN N.V., Affymetrix, and Illumina, among others Dominate the Gene Expression Analysis Market
Over the years, gene expression analysis techniques have evolved significantly and are being widely used in the areas of diagnostics, drug discovery, and treatment of certain diseases. In the past few years, the market has witnessed significant technological advancements, as companies have introduced new products in the market. This technologically driven market has witnessed a large number of offerings by big as well as small companies. In order to be competitive in this market, companies must be focused on delivering superior quality products that are technologically advanced.
Based on the revenues gained from gene expression analysis products, the overall gene expression analysis market is dominated by six major players contributing to approximately XX% of the gene expression analysis market. These players include Life Technologies (U.S.), QIAGEN N.V. (Netherlands), Affymetrix, Inc. (U.S.), Illumina, Inc. (U.S.), Roche Diagnostics (Switzerland), Agilent Technologies (U.S.), and Bio-Rad Laboratories (U.S.).
Life Technologies (U.S.) is a leading player in the gene expression analysis market. The firmís leading position in the market is attributed to its wide product portfolio including genomic profiling, gene expression profiling, and microarray analysis instruments, and its wide geographic presence spanning across North America, Latin America, Europe, Africa, the Middle East, and Asia-Pacific. In order to sustain its leading position in the market, Life Technologies focuses on launching new products and entering into partnerships and collaborations.
QIAGEN N.V. is another leading player in the market. The firm marks its prominence in the market by offering a wide range of genotyping and gene expression analysis products for cancer research, PCR technologies, assay technologies, as well as next-generation sequencing products. The company has been successfully expanding its consumer base by providing complete solutions through new product developments. The firm launched a complete series of the QIAsymphony Automation Platform for streamlining laboratory workflow in molecular testing. QIAsymphony sample preparation and assay setup modules were introduced in 2008 and 2009, respectively; and in 2010, a fully integrated QIAsymphony RGQ system was launched. In addition to this, QIAGEN focuses on geographic expansions in emerging countries such as India, China, South Korea, Brazil, Russia, Mexico, and Turkey, to distribute its genomics products.
Various key growth strategies such as new product launches, acquisitions, expansions, agreements, partnerships, collaborations, and joint ventures were mainly adopted by key players such as QIAGEN N.V. (Netherlands), Agilent Technologies (U.S.), Illumina, Inc. (U.S.), Life Technologies Corporation (U.S.), and Roche Diagnostics Corporation (Switzerland). These players adopted these strategies to increase their market shares. For instance, in October 2013, QIAGEN acquired CLC bio, a leading bioinformatics analysis software provider. This acquisition will position QIAGEN as a leader in next-generation bioinformatics, with a focus on biological analysis and interpretation/reporting. Thus, companies are investing efforts and resources in these strategies to help them gain a competitive advantage in the gene expression analysis market.
Gene Expression Analysis Market by Technology (DNA Microarray, Real-Time PCR, Next Generation Sequencing), Consumables (DNA Chips, Reagents), Services (Gene Profiling, Bioinformatics, Data Analysis Software) & Applications] - Global Forecast to 2018
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252